Standard BioTools director granted RSUs and options
STANDARD BIOTOOLS INC. director Carey Thomas D. reported equity compensation grants consisting of restricted stock units and stock options.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
STANDARD BIOTOOLS INC. director Carey Thomas D. reported equity compensation grants consisting of restricted stock units and stock options. He received 99,116 RSUs that vest in full on the earlier of June 18, 2027 or one day before the next annual stockholders’ meeting, subject to continued service. Each RSU converts into one share of common stock at vesting. He was also granted stock options for 263,884 shares at an exercise price of $0.8297 per share, vesting in twelve equal monthly installments beginning on July 18, 2026, and expiring on June 18, 2036. Following these awards, he directly holds 344,456 shares of common stock and 263,884 stock options.
Insider Trade Summary
Grant/Award: 363,000 shares
Grant/Award
2 txns
Insider
Carey Thomas D.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to buy) | 263,884 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 99,116 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to buy) — 263,884 contracts (Direct);
Common Stock — 344,456 shares (Direct)
Footnotes (2)
- F1. Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 18, 2027 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.
- F2. The Option becomes exercisable in twelve equal monthly installments beginning on July 18, 2026, subject to the Reporting Person's continued service through the applicable vesting date.
Key Figures
RSU grant size: 99,116 units
Option grant size: 263,884 shares
Option exercise price: $0.8297 per share
+3 more
6 metrics
RSU grant size
99,116 units
Restricted Stock Units vesting by June 18, 2027 or earlier
Option grant size
263,884 shares
Stock options linked to common stock, compensation grant
Option exercise price
$0.8297 per share
Conversion or exercise price for stock option grant
Option expiration
June 18, 2036
Expiration date for the stock option award
Post-grant share holdings
344,456 shares
Total common shares directly held after RSU grant
Underlying option shares
263,884 shares
Common shares underlying the stock option grant
Key Terms
Restricted Stock Units ("RSUs"), Stock Option (Right to buy), vest, exercise price, +1 more
5 terms
Restricted Stock Units ("RSUs") financial
"Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 18, 2027"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (Right to buy) financial
"Stock Option (Right to buy) with an exercise price of 0.8297 per share"
vest financial
"RSUs that vest in full on the earlier to occur of June 18, 2027"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercise price financial
"conversion_or_exercise_price of 0.8297 per share for the option grant"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date of 2036-06-18T00:00:00.000Z for the stock option"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did LAB director Carey Thomas D. report on this Form 4?
Director Carey Thomas D. reported receiving two equity awards: 99,116 restricted stock units and stock options for 263,884 shares. Both grants are compensation-related and subject to vesting conditions tied to his continued service with Standard BioTools.
What are the terms of the RSU grant reported by LAB director Carey Thomas D.?
The RSU grant covers 99,116 units that vest in full on the earlier of June 18, 2027 or one day before Standard BioTools’ next annual stockholders’ meeting. Vesting is conditioned on his continued service, and each vested RSU delivers one share of common stock.
What are the key details of the stock option grant to LAB director Carey Thomas D.?
The stock option grant covers 263,884 shares of common stock at an exercise price of $0.8297 per share. The options vest in twelve equal monthly installments starting July 18, 2026, contingent on continued service, and expire on June 18, 2036 if not exercised.
Are the LAB equity awards to Carey Thomas D. open-market purchases or compensation grants?
The reported transactions are compensation grants, not open-market purchases. The Form 4 uses transaction code A for grant or award, with a zero purchase price, and footnotes describing vesting schedules for RSUs and options based on continued service with Standard BioTools.
AI-generated analysis. How Rhea-AI works. Not financial advice.
